Purpose: The purpose of this study was to develop a new 3D dynamic carbon-13 compressed sensing echoplanar spectroscopic imaging (EPSI) MR sequence and test it in phantoms, animal models, and then in prostate cancer patients to image the metabolic conversion of hyperpolarized [1-
| I NT ROD UCTI ON
Hyperpolarized (HP) 13 C MR using dissolution dynamic nuclear polarization (dDNP) has been shown in over 100 published animal studies to provide unprecedented information on previously inaccessible aspects of biological processes by detecting endogenous, nontoxic 13 C-labeled probes that can monitor enzymatic conversions through key biochemical pathways. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] A human Phase 1 clinical trial using a custom-designed polarizer in a cleanroom demonstrated the safety and feasibility of HP 13 C-pyruvate MRI in prostate cancer patients. 12 This clinical trial indicated the potential to characterize the extent and aggressiveness of prostate cancer in individual subjects to ultimately benefit clinical treatment decisions and to monitor treatment response that is an unmet clinical need. 12 However, the acquisition techniques used in that first human study provided only slice dynamic information on the conversion of [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]pyruvate to [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]lactate and single time point 3D 13 C MRSI data acquired over 12 s. To be clinically useful, dynamic 3D acquisitions with full gland coverage are required and with a spatial resolution fine enough to study 0.5 cm 3 tumors and a temporal resolution adequate to measure quantitatively the conversion rate, k PL , of pyruvate to lactate. The goal of this project was to develop a new dynamic and volumetric acquisition to detect HP pyruvate uptake and enzymatic conversion throughout the prostate with high spatial and temporal resolution. A new 3D dynamic compressed sensing echoplanar spectroscopic imaging (3D dynamic CS-EPSI) sequence was developed and comprised of spectral-spatial RF excitations with multiband and variable-flip schemes, followed by a compressed-sensing EPSI readout using random blip encoding. The 3D dynamic imaging protocol was tested in phantoms, transgenic mice of prostate cancer (TRAMPs), and rats before translating this approach for human studies. The translational challenges, including larger imaging volume, reduced peak RF power and lower B1 inhomogeneity were addressed through the optimization of pulse design and sequence parameters.
| M ETH ODS

| Pulse sequences
A 3D dynamic CS-EPSI sequence was designed and optimized to provide more efficient, higher SNR hyperpolarized 13 C MR scans of pyruvate metabolism in animals and humans. The backbone of this sequence consists of a spectral-spatial RF excitation pulse, followed by a compressed sensing EPSI readout. Prior TRAMP studies 1, 13 used a double-spin echo (DSE) refocusing pulse to provide narrow spectral lines and improve SNR (TE/TR 5 150/250 ms) ( Figure 1A ). For patient studies, no spin-echo refocusing pulses were used ( Figure 1B ) because of peak power limitations and the increased B 1 inhomogeneity for the clamshell transmit coil. The estimated SAR of the 3D CS-EPSI sequence was well below the Food and Drug Administration (FDA) requirements. The 3D readout scheme used pseudorandom "blip" encoding in the k x -k y -dynamic directions and flyback EPSI in the k z -k t dimensions. The compressed sensing reconstruction takes advantage of the sparsity in the spatial and temporal-wavelet dimensions to recover undersampled k-space locations using L1-minimization with total variation penalty, achieving 18 3 acceleration. The EPSI readout enabled another 16-fold acceleration compared to conventional chemical-shift imaging by the rapid simultaneous spectral-spatial encoding. 14, 15 A combined 288 3 acceleration factor condenses a 10-min fully sampled MRSI acquisition into a 2-s undersampled time interval. Acquiring data without DSE refocusing pulses required modification of the prior compressed sensing reconstruction algorithm 1, 15 to incorporate spectral phasing and minimize linewidth broadening. The reconstruction included a linear phase correction to account for the additional phase caused by sampling delay.
| RF pulses design
The RF excitation pulse provided multiband excitation to account for the metabolic conversions between 13 C pyruvate and lactate. Moreover, a "variable flip angle" scheme was applied, where the excitation flip angle on each metabolite was progressively increased to account for the loss from previous excitations and the intrinsic T 1 relaxation. The flip angles were calculated based on a "T 1 -effective" scheme, ensuring adequate pyruvate SNR while maximizing total lactate SNR for robust modeling of metabolic conversion and parameter estimation. 16 The spectral-spatial pulses were designed using the SS-RF toolbox developed by Larson et al. 17 A new spectral-spatial RF pulse was designed and generated to account for the limitation on peak power in the clinical setup (Figure 2A ). The new SSRF pulse has a peak B 1 of 0.597G and duration of 6.3 ms, which is a 67% reduction of peak power and 30% reduction in length compared to our preclinical designs (peak B 1 5 1.796 G, duration 5 8.9 ms, applied in the preclinical data sets in this study). The pulse bandwidth was 793 Hz. The ripple was set to <1% in both passband and stopband to ensure reasonably homogeneous pulse profile. The 13 C RF calibration protocol is summarized in the Supporting Information.
| 3D imaging coverage
The 3D CS-EPSI sequence 15 was designed to offer full 3D
coverage for the regions of interest with high spatiotemporal resolution in both preclinical 1 and now clinical research in this study. In TRAMP mice studies, the sequence was configured to cover the entire animal, which has 2 advantages. First, the coverage allows for blood vessels such as the iliac F IGUR E 2 New spectral-spatial RF pulses were designed using the ss-RF toolbox by Larson et al. 17 (A) The 6.3 ms-long RF pulse excites 13 C pyruvate and lactate with independent variable flip angles. Red is magnitude, blue is real, and green is imaginary components. The peak B 1 of 0.597 G is a 67% reduction from that used for preclinical studies. (B) Phantom data excited with progressive-increasing flip RF showed good agreement with simulated profile.
artery to be included, and therefore enables acquisition of the arterial input function (AIF) and potentially factor perfusion into the dynamic modeling. Second, it allows not only imaging the primary tumor, but common metastatic sites, such as peri-arterial (PA) and peri-renal (PR) lymph nodes. In addition, it monitors key physiological regions (e.g., kidney and liver) for possible abnormalities associated with prostate cancer. In rat studies, the FOV was chosen to extend through the rat trunk for similar reasoning. In clinical exams, the sequence covers the full prostate gland from base to apex, including the peripheral, central, and transition zones. The 581 Hz-spectral bandwidth ensures inclusion of the 2 main biomarkers in preclinical studies (i.e., HP-13 C pyruvate and lactate). Note the urea phantom was spectrally aliased to conserve spectral bandwidth for improved SNR efficiency.
| MRI experiments
Eleven sets of hyperpolarized 13 C dynamic MRSI were acquired on a total of 6 TRAMP mice and 3 healthy rats using the 3D dynamic CS-EPSI. 3 TRAMPs had histologically aggressive late stage, and 3 had early stage tumors in this study. Data sets (N 5 8) were collected from TRAMP experiments, with 2 mice studied twice (on different days) among the cohort of 6. Two mice were studied twice among the cohort of 6. [1-
13
C]pyruvate was polarized by a GE SPINlab clinical polarizer (GE Healthcare, Waukesha, WI) using the dDNP technique for 2 h, yielding 25-35% pyruvate polarization. The 13 C substrate was rapidly dissolved and injected into the subject animal through a tail vein catheter. For the TRAMP studies, $350 lL bolus was injected over 15 s, whereas the rats received $3 mL bolus over 12 s. In both cases, the sequence was initiated at t 5 15 s since the beginning of injection. All studies were performed on a 3T clinical scanner (GE Healthcare). The mouse and rat studies were done using custom-built, dual-tuned 1 H and 13 C mouse and rat coils, respectively. Dose per unit weight was $10 mL/kg for TRAMP mouse and 6 mL/kg for rat, both injected with 80 mM solution.
For TRAMP mouse studies, the 3D CS-EPSI sequence was chosen to provide a spatial resolution of 3.3 3 3.3 3 5.4 mm, a temporal resolution of 2 s, a FOV of 4 3 4 3 8.6 cm, a spectral BW of 581 Hz, and 18 time frames in 36 s. For rats, the FOV and the spatial voxel size were both doubled to provide larger coverage (spatial resolution 5 6.7 3 6.7 3 10.8 mm, FOV 5 8 3 8 3 17.2 cm), whereas temporal resolution and acquisition window remained the same as TRAMP scans. The HP- 13 C voxel volume for mouse and rat scans were 0.059 and 0.480 cm 3 , respectively. A proton T 2 -FSE sequence was prescribed for anatomical reference in TRAMP exams, whereas a bSSFP sequence served as the reference in rat studies.
Phantom studies were conducted using the full clinical configuration with clamshell transmit and endorectal receive coils. The phantom setup includes a built-in 13 C-urea phantom positioned on the receive coil (8 M, 600 lL) and 2 ethylene glycol phantoms (natural abundance, 13 C concentration 5 0.17 M). The pulse sequence for the clinical studies was used.
For the human study (N 5 1), GMP-grade sterile [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C] pyruvic acid with 15 mM trityl radical was polarized in Spinlab for $2 h, dissolved with sterile water, and subjected to radical filtration, neutralization, and sterile filtration into a Medrad syringe. An automatic post-dissolution QC reported key parameters including pyruvate concentration (253 mM), polarization level (37%), radical concentration (0.7 lM), pH (7.8), and temperature (32.9 8C), and a pharmacist determined that the bolus met all safety standards for injection. Dosage was calculated based on patient weight for 0.43 mL/ kg of the 250 mM sterile pyruvate solution. The injection used a power injector (Spectris Solaris, Medrad, Saxonburg, PA) at a rate of 5 mL/s, followed by flush of saline. Total injection time was $10-15 s depending on patient weight.
In the clinical setup, a clamshell volume coil was used for 13 C transmit and a dual-tuned endorectal coil for receive. The resolution for the patient study was as follows (spatial resolution 5 8 3 8 3 8 mm isotropic, FOV 5 9.6 3 9.6 3 12.8 cm). Acquisition window was 36 s for the patient study, with voxel volume of 0. The human research was conducted with the approval from Institutional Review Board, and all animal studies were conducted in accordance with the policies of Institutional Animal Care and Use Committee at University of California, San Francisco.
| Data analysis
The hyperpolarized 13 C 3D CS-EPSI data were reconstructed using an in-house command-line script combined with MAT-LAB (The MathWorks, Natick, MA) routine. 1, 15 A combina-
tion of an open-source SIVIC image processing software 18 and MATLAB was used for examination of the fully 3D spectrum voxel-by-voxel, over a specific slice and orientation, or across a given time frame. Overlay of HP-13 C images, image-based statistics or modeled metabolic and perfusion indices such as k PL and k trans , with the anatomical reference scans was performed for better lesion identification and analysis.
Dynamic modeling of the pyruvate to lactate conversion was calculated using a 2-site exchange model including a pyruvate arterial input function (AIF) assumed to be a boxcar function, defined by injection rate r 0 , similar to the model reported by Zierhut et al. 19 The model used is described in the following ODE form dM pyr ðtÞ=dt5r 0 Á e 2qt Á ½uðtÞ2uðt2aÞ2ðq1k PL ÞM pyr ðtÞ;
(1)
where M x is the magnetization of metabolite x and k PL is the pyruvate-to-lactate conversion rate constant. q is the relaxation coefficient, where q 5 1/T 1 , uðtÞ is the unit step function, and a is the bolus duration. Here, the alanine fitting was included as it could improve the quantitative accuracy of k PL . The rate coefficient for pyruvate-to-lactate conversion, k PL , was computed by applying the metabolic models to the in vivo HP- 13 C dynamic profile. The signal curves were fitted to the dynamic models using the non-linear least squares analysis. The mean was calculated over the manually selected tumor ROI for the k PL estimation, where only voxels with >85% tumor were incorporated. RF excitations and relaxation T 1 were included in the model to account for signal loss, F IGUR E 4 Similar to the "DSE" mode, the in vivo dynamics of 13 C biomarker acquired using the 3D dynamic CS-EPSI "FID" mode can be quantitatively analyzed by compartmental exchange models. Pyruvate and lactate dynamics were overlaid on T 2 -FSE scan in a low-grade TRAMP tumor. The calculated k PL value was 0.0297 (s
21
).
F IGUR E 5 Pyruvate-to-lactate conversion in the kidneys of healthy rat is visualized in this 13 C image overlaid on bSSFP reference. The calculated k PL was 0.0058 (s
where T 1 was assumed to be equal for all 13 C metabolites. The reverse conversion rate k LP was assumed to be 0 in the model because it is much lower compared to the forward reaction in physiological conditions, and such assumption improves the stability of fitting computations. 19, 20 3 | R ES ULT S
| Preclinical studies
The acquisition was delayed by 15 s from the beginning of injection. Immediately following the arrival of HP-pyruvate in TRAMP tumor, lactate dehydrogenase (LDH) rapidly catalyzed the reduction reaction to HP-lactate. This reflected the upregulated LDH gene expression/activity in cancer as found previously.
1 Pyruvate signal displayed its maximum near the beginning of the acquisition and then decreased because of the metabolic conversion, the RF excitation pulses, and the T 1 relaxation. The lactate increased at the beginning of the sequence because of the rapid pyruvate-to-lactate conversion, reaching maximum at approximately t 5 14 6 4 s. The decreasing lobe at the latter half of the lactate curve indicated the timing where the combined loss from progressively increasing flip angle and T 1 relaxation exceeded the contribution from pyruvate conversion. Alanine was converted to a much lower degree from pyruvate as a key step in gluconeogenesis pathway, which is governed by the alanine transaminase. The alanine time curve approached maximum at t 5 20 6 6 s. The amount of alanine production was only a fraction of lactate in the TRAMP tumor, whereas higher alanine level can be seen in the liver of both cancerous and healthy animals. To investigate the feasibility of imaging larger FOVs in vivo, we applied the 3D CS-EPSI sequence on 3 healthy rats. Rapid pyruvate perfusion/uptake into the kidney was observed since the beginning of the sequence, namely at around $t 5 3 s post-injection. Appreciable amount of lactate exchange was detected as well ( Figure 3 ). Lactate and alanine production was also found in rat liver (data not shown). These outcomes were highly consistent with the previous observations on HP- 13 C rat studies. 21, 22 From TRAMP studies (Figure 4) , the mean SNR, summed across time, of total carbon was 69.2 6 28.4 for tumor, 115.5 6 45.8 for vena cava, and 135.5 6 56.2 for kidneys with $25-35% polarization on dissolution. In the rat scans ( Figure 5 ), both FOV and voxel size were doubled from mice. High SNR was found in both rat kidney (172.5 6 100.3) and liver (85.7 6 50.1). Such SNR was adequate for both direct data visualization and dynamic modeling of metabolic interconversion. The mean size of TRAMP tumors, 2.2 cm 
| Clinical phantom studies
Phantom studies were conducted using clinical setup, sequence, and coils. The signal pattern on the built-in urea phantom was found to be of higher homogeneity compared to the ethylene glycol phantoms (Figure 3) . Such signal profile probably resulted from the reduced sensitivity in regions further away from the endorectal coil. The phantom data was acquired with our 3D CS-EPSI sequence in tandem with the new spectral-spatial RF pulses with reduced peak power and duration. On both pyruvate and lactate bands, the phantom dynamics showed good fitting agreement with the simulated signal profile ( Figure 2B ). The apparent SNR of ethylene glycol phantom was 16.1, and of urea phantom was 354 at the final time point, where the 13 C compounds were individually excited by the lactate excitation band with a mean flip angle $40 8.
| Patient data
The subject of the human study testing the feasibility of the new 3D CS-EPSI methods was a 66-year-old male patient with biopsy-confirmed prostate cancer of stage T2c, with PSA level of 6 ng/mL and PI-RADS score of 4/5. At radical prostatectomy (RP), bilateral Gleason 4 1 3 was found at the midgland of the prostate. Figure 6 depicts the pyruvate and lactate area under curve (AUC) overlays in the prostate region overlaid on T 2 -weighted reference scan. It demonstrated full gland coverage of this new sequence, from apex to base, with a spatial resolution of 8 3 8 3 8 mm isotropic (volumetric 5 0.5 cm 3 ). Whereas pyruvate intensities encompass the prostate gland as well as some surrounding vasculatures, regions of elevated conversion to lactate correlated with cancer in the bilateral pathology data of this patient. Figure 7 illustrates the temporal dynamics in a single slice containing bilateral prostate cancer confirmed at RP. HP- 13 C pyruvate is seen to perfuse into the vasculature surrounding the prostate, and the bolus entered prostate $t 5 10 s into the dynamic 3D acquisition. Rapid conversion to lactate in cancerous regions was observed to occur at $t 5 20 s.
The biopsy-proven Gleason 4 1 3 tumor in the right peripheral zone exhibited more than 4-fold higher pyruvateto-lactate conversion (k PL ) compared to normal-appearing regions, reflecting high LDH enzymatic activity. The tumor size was $1.5 cm . Figures 8C and 8D showed the HP- 13 C spectra and dynamics in a representative voxel of this tumor versus a normalappearing region voxel. The dynamic curves were corrected for progressive flip angles to show the estimated HP magnetization for kinetic modeling visualization purposes. The raw signal of both pyruvate and lactate appears to monotonically increase until the end of acquisition ( Figure 8B ) because of the progressively increasing flip angles, whereas the corrected signal (i.e. the HP magnetization) shows the pyruvate maximizing near $t 5 20 s post-injection and that of lactate $30 s and decreasing toward the end ( Figure 8C ). The tumor region also corresponds to darker region in T 2 -weighted FSE image ( Figure 8A, top, as encircled by the red box) , and high intensity in high b-value ADC maps ( Figure 8A, bottom) , both of which exhibited good consistency with biopsy and HP 13 C findings. The bilateral midgland Gleason 4 1 3 cancer found at radical prostatectomy was also consistent with the k PL map in Figure 8E , where the tumor in the right was larger than the one in the left.
In the right midgland cancer, the apparent SNR calculated for pyruvate was 104, and for lactate, it was 10.7 at the last time point. The mean SNR over the acquisition for pyruvate was 45.2 and 6.1 for lactate. The mean SNR over all time points for total carbon was 51.3. In normal-appearing regions, the mean SNR of total carbon in this patient was 48.2, comparable to the tumor region.
| DI S CU S S IO N
Because HP 13 C MR encodes chemical as well as spatial information, this new molecular imaging technique allows the simultaneous detection of multiple biologic compounds and metabolic products with sensitivity enhancements of >10,000-fold. 23 This technique therefore presents the fields of oncology and medical imaging with an opportunity to improve our ability to investigate human disease and to ultimately translate these techniques into the clinic for more individualized patient care. The translation from animal to clinical HP- 13 C imaging faces the challenges of larger imaging volume, reduced peak RF power, and higher B 1 inhomogeneity. To address these challenges, specialized sequence modifications were developed including a low-power spectral spatial RF excitation, "FID" acquisition mode and associated reconstruction methods, 3D coverage of the entire prostate with 0.5 cm 3 spatial and 2-s temporal resolution for prostate cancer patient imaging. This study was designed to determine and test the sequence properties and signal behavior transitioning from mouse studies to rats and, then to a human subject, with the intent to optimize the performance and robustness of this new 3D dynamic acquisition approach and then determine its feasibility for imaging patients. One major sequence modification made for the translation to human imaging was in the RF pulse design. The new spectral-spatial RF pulse provide 67% savings in peak B 1 by means of relaxing the constraints on urea flip angle, which accounts for the reduced peak RF power from clamshell transmit coils in clinical setup compared to preclinical settings. The designed peak B 1 was chosen to be $60% the nominal maximum allowable power for the transmit coil to provide sufficient headroom in transmit power allow for varying coil loading when scanning different patients. The 1 ppm ($30 Hz) passband for each metabolite in this spectral-spatial pulse was reasonably wide to account for offresonance, which is typically <0.2 ppm ($6 Hz) for TRAMP mice and <0.5 ppm ($15 Hz) for human prostate. The timebandwidth of 5 provides good compromise between pulse duration, peak power, and transition profile sharpness ( Figure  2A ). The reduction in RF pulse width (8.9 to 6.3 ms) shortened the echo time, which may slightly improve SNR given limited T 2 and T Ã 2 . The phantom signal curve agrees well with the simulated signal profile, indicating that the excitation pulses can be confidently generated with the clinical coil configuration. Removing the DSE refocusing pulses also mitigated the issue of limited peak RF power. The mean SNR were comparable in TRAMP prostate tumor in the DSE-enabled sequence from prior studies and the new sequence in this study (N 5 8, SNR DSE 5 61.6 6 43.6, SNR FID 5 69.2 6 28.4, P > 0.3).
Imaging a larger subject using the 3D dynamic CS-EPSI acquisition protocol provided a way to investigate the sequence parameters and signal behavior because of increasing FOV. The rat scans in this study use a dual-tuned rat coil that was $5 times the volume of mouse coil. The FOV and voxel size were doubled both in the phase encode and EPSI readout direction (in-plane resolution: mouse 5 3.3 mm, rat 5 6.7 mm; axial resolution: mouse 5 5.4 mm, rat 5 10.8 mm), giving 4 3 voxel volume. The total injection dose also increased by $6-fold. However, rat received lower HP- 13 C dose per unit weight ($60% that of TRAMP). In addition, the larger coil volumes inherently lead to decreased sensitivity compared to mouse setup. The other sequence parameters (e.g., flip angles, temporal resolution, and undersampling ratio) remained the same. Substantial pyruvate and lactate were observed in rat kidneys just like in TRAMP mice tumors. The SNR did not deteriorate in rat relative to mouse (Figures 4 and 5 ). As such, transitioning to rat scans revealed the key elements to scaling up the sequence, and this protocol showed robustness in signal and image quality with larger imaging subjects and coils. A 2-s temporal resolution was chosen for human protocol identical to that in TRAMP studies. In TRAMP scans, this consistently provided >30 (apparent) SNR for both pyruvate and lactate ($25-35% polarization), which translated into <3% error in quantitative metabolism models for k PL evaluation based on simulations. For the clinical study, the pyruvate SNR was similar to TRAMP ($30), while lactate SNR was relatively lower ($6). Two primary sources of uncertainty contribute to the apparent SNR of this 3D CS-EPSI acquisition-the data noise and CS reconstruction errors. Referring to Figure 3 of the paper by Larson et al., 15 the reconstruction error was <0.001 for SNR of 45 and <0.007 for SNR of 6. Therefore, it can be concluded that the data noise was dominant source of error under both clinical and mouse scheme. SNR improvement is theoretically possible through a longer temporal resolution, because it results in effective signal averaging and decrease of undersampling ratio. Nevertheless, a longer temporal resolution can create temporal blurring and ambiguity on timing of dynamic curve, which can negatively impact quantitative modeling. In the patient research, the acquisition began at t 5 5 s post-injection, compared to the t 5 0 s in mouse studies, whereas both shared the same 2-s temporal resolution. The acquisition time window covered both bolus dynamics and pyruvate-to-lactate conversion in human prostate cancer, whereas the TRAMP scan focused more on the latter half of the pharmacokinetics that mainly reflected pyruvate metabolism. A main reason for the 5-s delay in human studies was to prevent hyperpolarized magnetization in the intravenous tubing and arm being excited by the clamshell transmit coils. Because at the end of the injection, the bolus could still be traversing through the antecubital vein, which is typically located inside the "hot" zones of the transmitter, the delay allows hyperpolarized bolus to perfuse into tumor region before RF excitation.
In clinical hyperpolarized 13 C imaging, because of the absence of arterial coverage or perfusion markers, it is more challenging to account for pharmacokinetic parameters such as circulation and AIF. In contrast, because the bolus delivery was more rapid in small animals (e.g., TRAMP mice), and a reference AIF was relatively easy to estimate using the HP 13 C urea through arterial voxels according to a preclinical co-polarized imaging study of TRAMP tumor, 1 the sequence can be configured to put more focus on net metabolism by acquiring at a longer (15 s) delayed window. 1, 24 Additionally, the circulation and bolus delivery is generally slower in human versus small animals. Therefore, carefully selecting an acquisition window that both accounts for pyruvate infusion and pyruvate-lactate conversion benefits the clinical quantitation of prostate tumor metabolism. Prostate cancer is a major health concern in the United States with >160,000 new cases per year and >26,000 deaths. 25 Because of increased screening using serum prostate specific antigen (PSA) and extended-template transrectal ultrasound (TRUS) guided biopsies, patients with prostate cancer are being identified at an earlier and potentially more treatable stage. Unfortunately, the aggressiveness of individual tumors cannot be predicted with great confidence in individual patients using currently available clinical and imaging prognostic data. [26] [27] [28] [29] [30] using single-slice 1D dynamic, 2D dynamic, and 3D single time point acquisitions. This clinical trial indicated the potential to characterize the extent and aggressiveness of prostate cancer in individual subjects to ultimately benefit clinical treatment decisions and to monitor treatment response. However, the acquisition methods used in that trial did not provide simultaneously the required spatial and dynamic temporal resolution necessary for optimal HP 13 C MR clinical research studies. Development and translation of 3D dynamic HP 13 C MRSI offers a new method to quantitatively analyze metabolism in human prostate cancer throughout the gland. In this study, the human 3D MRSI acquisition demonstrated the ability to obtain dynamic information on the conversion of [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]pyruvate to [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]lactate that is catalyzed by lactate dehydrogenase (LDH) that is upregulated in prostate cancer. Adequate SNR and temporal resolution enabled the calculation of k PL maps with a spatial resolution of 0.5 cm 3 . This supports the use of this 3D acquisition approach in future studies to investigate in sufficiently large patient populations prostate cancer aggressiveness and response to therapy. Importantly, the capability to image biochemical processes and visualize diseases with high spatiotemporal resolution opens the door to many potential HP 13 C translational and research applications. For instance, high lactate/pyruvate ratios were detected in various cancer types such as xenografts of human brain tumor, 32 renal carcinoma cells, 33 and breast tumor xenografts. 7 Modulation of lactate production was found in tumors subjected to chemo 34 and targeted therapy. 35 Besides cancer, HP 13 C imaging has been used to study kidney urea transporters, 36 diabetes and gluconeogenesis, 37 cardiac diseases, 38 and neurodevelopment. 39 
| C ONCL US I ONS
This new 3D dynamic MRSI acquisition method incorporating new spectral-spatial RF pulses, "FID" readout, and modified CS reconstruction addressed the challenges of larger imaging volumes and reduced available peak RF power required for human studies. Scalability in acquisition, reconstruction, and quantitation methods was demonstrated by the satisfactory image quality, SNR, and apparent kinetic rate constants between cancer-normal during the transition from mice to human patient studies. The results demonstrate the feasibility to characterize prostate cancer metabolism in the clinical setting using this new 3D dynamic HP MR technique to quantify and image the kinetic rate constant, k PL , of 
